No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Jacobson Pharma Corporation Limited, a subsidiary of Kingshill Development Limited, specializes in the production, promotion, and distribution of generic medications and branded healthcare products. Its market reach extends across Hong Kong, mainland China, Macau, Singapore, and international territories. The company offers a broad selection of generic pharmaceuticals targeting diverse medical conditions, including respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergic, scar treatment, oral anti-diabetic, and anti-infective categories. Specific examples comprise arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. In addition to generics, the company provides branded medications, health and wellness products, and traditional Chinese remedies. Prominent proprietary Chinese medicines include Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. Its operations also extend to trading medical provisions, procuring packaging materials, distributing herbal and health-related goods, conducting research and development, and managing property holdings. The company distributes its offerings to a wide range of clients, including hospitals, clinics, authorized pharmacies, independent physicians, retail outlets, and trading companies. Founded in 2016, Jacobson Pharma Corporation Limited is headquartered in Kwun Tong, Hong Kong.
www.jacobsonpharma.comNo one on the platform currently holds 2633.HK.
No tracked institution reports a position in 2633.HK as of their last filing.
No one on the platform has traded 2633.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 10.3% | 9.2% | 8.3% | — | — | — |
| Rev. Growth % | -0.5% | 1.7% | ||||
| Profit Margin % | 19.2% | 16.3% | 15.2% | |||
| Free Cash Flow Margin % | 12.8% | 21.8% | 19.1% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2031 | $1.8B | — | $0.10 | $0.09–$0.10 | — | 1 |
| 2032 | $2.0B | +7.0% | $0.11 | $0.11–$0.12 | — | 1 |
| 2033 | $1.5B | -21.4% | $0.14 | $0.13–$0.14 | — | 1 |
| 2034 | $1.6B | +5.6% | $0.16 | $0.15–$0.17 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| $1.95 |
| -2.02% |
| $2.5B |
| — |
| 2235.HKMicroTech Medical (Hangzhou) Co., Ltd. | $6.77 | -0.66% | $2.8B | — |
| 2348.HKDawnrays Pharmaceutical (Holdings) Limited | $0.98 | +0.00% | $1.5B | — |
Source: Financial Modeling Prep · peers by sector/industry